PT  - JOURNAL ARTICLE
AU  - Carmen Maria Valencia Soto
AU  - María Victoria Villacañas Palomares
AU  - Adela Garcia-Avello Fernández-Cueto
AU  - Sara Barbadillo Villanueva
AU  - Virginia Martínez Callejo
AU  - María Ochagavía Sufrategui
AU  - Pedro Muñoz Cacho
AU  - Marta Valero Domínguez
TI  - Predictive value of immune-related adverse events during pembrolizumab treatment in non-small cell lung cancer
AID  - 10.1136/ejhpharm-2021-003038
DP  - 2024 Jan 01
TA  - European Journal of Hospital Pharmacy
PG  - 40--45
VI  - 31
IP  - 1
4099  - http://ejhp.bmj.com/content/31/1/40.short
4100  - http://ejhp.bmj.com/content/31/1/40.full
SO  - Eur J Hosp Pharm2024 Jan 01; 31
AB  - Objectives Several studies have reported the role of immune-related adverse events as a predictor of clinical benefit, but few have properly described these findings in advanced or metastatic non-small cell lung cancer treated with pembrolizumab. This study aimed to evaluate the association between immune-related adverse events development and clinical outcomes in the aforementioned group of patients.Methods We conducted a retrospective study in patients with advanced or metastatic non-small cell lung cancer treated with pembrolizumab. Overall response rate, progression-free survival and overall survival were evaluated according to the appearance, subtype and number of immune-related adverse events developed. We report the results of the immune-related adverse events analysis and the potential correlation between immune-related adverse events and clinical outcomes. Univariate and multivariate analyses were performed to evaluate this relationship.Results A total of 94 patients were analysed; 60 of them developed immune-related adverse events. Patients with immune-related adverse events had a significantly higher overall response rate compared with the non-immune-related adverse events group (34% vs 8.5%, χ2=0.005). Median progression-free survival was statistically significant in favour of patients with at least one immune-related adverse event (p=0.015). Median overall survival was not reached in patients with ≥1 immune-related adverse events, compared with 8 months (95% CI 0.6 to 15.4 months) in those without immune-related adverse events. Patients who developed ≥2 immune-related adverse events had longer median progression-free survival (11 vs 4 months, not statistically significant) and overall survival (not reached vs 11, p=0.022) compared with those with ≤1 immune-related adverse events.Conclusions Obtained data showed that patients with immune-related adverse events occurrence had significantly better overall response rate and longer progression-free survival and overall survival. This study highlights the role of immune-related adverse events as a predictor of survival in a real-life setting.Data are available in a public, open access repository.